What is he best known for?
The fields of study he is best known for:
Titin, Actinin, alpha 2, Obscurin, Molecular biology and Sarcomere are his primary areas of study.
His Titin study combines topics in areas such as Biophysics and Biochemistry, Myofibril.
His research in Biochemistry focuses on subjects like Nebulin, which are connected to Nemaline myopathy.
His Obscurin study integrates concerns from other disciplines, such as Genetics, Anatomy and Myosin.
In Sarcomere, he works on issues like Protein filament, which are connected to Nebulette, Actin, Repeated sequence and Nucleic acid sequence.
His Myotilin research is multidisciplinary, relying on both Telethonin and Myomesin.
His most cited work include:
- Titins: Giant Proteins in Charge of Muscle Ultrastructure and Elasticity (1006 citations)
- Cloning of the T gene required in mesoderm formation in the mouse (727 citations)
- Mutations of TTN, encoding the giant muscle filament titin, cause familial dilated cardiomyopathy. (455 citations)
What are the main themes of his work throughout his whole career to date?
His main research concerns Titin, Cell biology, Obscurin, Sarcomere and Molecular biology.
Siegfried Labeit has researched Titin in several fields, including Genetics, Biophysics and Myofibril.
His Cell biology study combines topics in areas such as Cardiology, Internal medicine, Dilated cardiomyopathy and Gene isoform.
His study explores the link between Sarcomere and topics such as Actin that cross with problems in Nebulin.
His work carried out in the field of Molecular biology brings together such families of science as Mutation, ANKRD1 and Serine.
As a part of the same scientific family, Siegfried Labeit mostly works in the field of Actinin, alpha 2, focusing on Anatomy and, on occasion, Molecular spring.
He most often published in these fields:
- Titin (63.70%)
- Cell biology (28.15%)
- Obscurin (26.67%)
What were the highlights of his more recent work (between 2013-2020)?
- Titin (63.70%)
- Internal medicine (14.81%)
- Dilated cardiomyopathy (7.41%)
In recent papers he was focusing on the following fields of study:
His scientific interests lie mostly in Titin, Internal medicine, Dilated cardiomyopathy, Cardiology and Cell biology.
Titin is a subfield of Sarcomere that he investigates.
His studies deal with areas such as Endocrinology and Gene expression as well as Internal medicine.
His studies in Cardiology integrate themes in fields like Animal model and Biopsy.
Siegfried Labeit usually deals with Cell biology and limits it to topics linked to Mutation and Molecular biology, Duchenne muscular dystrophy and Myofibril assembly.
Siegfried Labeit works mostly in the field of Genetics, limiting it down to topics relating to Obscurin and, in certain cases, Myotilin, Antibody, Point mutation, Mutant and Actinin, alpha 2, as a part of the same area of interest.
Between 2013 and 2020, his most popular works were:
- Approach to the diagnosis of congenital myopathies (155 citations)
- Diaphragm muscle fiber weakness and ubiquitin-proteasome activation in critically ill patients. (105 citations)
- Degeneration of neuromuscular junction in age and dystrophy. (97 citations)
In his most recent research, the most cited papers focused on:
His primary areas of investigation include Titin, Nicotinic acetylcholine receptor, Neuromuscular junction, Weakness and Myofilament.
His Titin research is classified as research in Cell biology.
His Nicotinic acetylcholine receptor research is multidisciplinary, incorporating perspectives in Postsynaptic potential, Agrin, Denervation, Dystrophy and Muscular dystrophy.
The various areas that Siegfried Labeit examines in his Neuromuscular junction study include Autophagy and Receptor, Biochemistry, Nicotinic agonist.
His study in Weakness is interdisciplinary in nature, drawing from both Medical diagnosis, Pathology, Physical examination and Muscle pathology.
His Myofilament study contributes to a more complete understanding of Biophysics.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
